LFCR (Lifecore Biomedical) Total Assets: $225.50 Mil (As of Mar. 2026)


LFCR Lifecore Biomedical Inc LFCR
55 GF Score
Price $4.97
GF Value $6.52
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Lifecore Biomedical Total Assets?

Lifecore Biomedical LFCR -3.78% 55 Total Assets is $225.50 Mil as of Mar. 2026. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.52 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Lifecore Biomedical's Total Assets for the quarter that ended in Mar. 2026 was $225.50 Mil.

During the past 12 months, Lifecore Biomedical's average Total Assets Growth Rate was -11.90% per year. During the past 3 years, the average Total Assets Growth Rate was -5.50% per year. During the past 5 years, the average Total Assets Growth Rate was -17.10% per year. During the past 10 years, the average Total Assets Growth Rate was -4.50% per year.

During the past 13 years, Lifecore Biomedical's highest 3-Year average Total Assets Growth Rate was 49.70%. The lowest was -24.30%. And the median was 6.50%.

Total Assets is connected with ROA %. Lifecore Biomedical's annualized ROA % for the quarter that ended in Mar. 2026 was -26.18%. Total Assets is also linked to Revenue through Asset Turnover. Lifecore Biomedical's Asset Turnover for the quarter that ended in Mar. 2026 was 0.10.

Lifecore Biomedical  (NAS:LFCR) Total Assets Explanation

Total Assets is connected with ROA %.

Lifecore Biomedical's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-59.92/( (232.177+225.499)/ 2 )
=-59.92/228.838
=-26.18 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Lifecore Biomedical's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=23.193/( (232.177+225.499)/ 2 )
=23.193/228.838
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Lifecore Biomedical Total Assets Related Terms

Lifecore Biomedical Total Assets Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Total Assets Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 502.92 274.70 253.55 253.96 239.34

Lifecore Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 237.69 239.34 235.20 232.18 225.50
LFCR
55GF Score
Lifecore Biomedical Inc LFCR
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Lifecore Biomedical's Total Assets for the fiscal year that ended in May. 2025 is calculated as

Total Assets=Total Equity (A: May. 2025 )+Total Liabilities (A: May. 2025 )
=1.336+238.006
=239.34

Lifecore Biomedical's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=-28.438+253.937
=225.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $225.50 Mil mean?
Lifecore Biomedical (LFCR) has a Total Assets of $225.50 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Lifecore Biomedical and its competitors.
Is Lifecore Biomedical's Total Assets too high?
Lifecore Biomedical's current Total Assets is $225.50 Mil. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Total Assets compare to ANIK and DERM?
Lifecore Biomedical's Total Assets of $225.50 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Lifecore Biomedical and its competitors. Lifecore Biomedical's current Total Assets is $225.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.52, compared to a current price of $4.97 — trading 23.8% below its estimated fair value. The current Total Assets is $225.50 Mil. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Total Assets is $225.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (LFCR) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of $4.97 is trading 23.8% below its estimated GF Value™ of $6.52. GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.

Key valuation signals for LFCR:

  • Total Assets: $225.50 Mil
  • GF Value™: $6.52 vs. price of $4.97 (23.8% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lifecore Biomedical Business Description

Other Exchanges LDE:Germany
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score

Get the complete analysis for LFCR

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.97
Price
$6.52
GF Value